May 16, 2023 / 01:30PM GMT
John Walden - JMP Securities LLC - Moderator
Good morning, everybody. Thanks for joining us. My name is John Walden, senior analyst here at JMP Securities and thanks for joining day two of our Life Sciences Conference. Pleased to be chatting with Clearside Biomedical and CEO, George Lasezkay. George, thanks for coming in and talking to us.
George Lasezkay - Clearside Biomedical, Inc. - President & CEO
John, thanks for having us. Great to be here.
Questions and Answers:
John Walden - JMP Securities LLC - ModeratorSo it seems the suprachoroidal space is really gaining momentum in the past, let's say, two to three years. But can you remind folks what you guys are working on the suprachoroidal space, how it's differentiated -- we're seeing different companies play around in development programs, which I think is good news. You have an approval now. Can you talk a little bit about how the story has changed in the past two to three years and then we can jump into where you are today and moving forward.
Trustpilot
